Philip J. Mease, MD, on a New Interleukin Antagonist as Therapy for Psoriatic Arthritis
Philip J. Mease, MD, from Swedish Medical Center, discusses results from a phase 2 clinical trial on tildrakizumab—an anti-interleukin-23p19 monoclonal antibody—and its potential as a therapeutic option for psoriatic arthritis.